Alzheimer Disease/Dementia

 
FDA Grants Fast Track Designation to Anti-MTBR Tau Antibody BMS-986446 for Alzheimer Disease
October 01, 2025

The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.

Donanemab (Kisunla) Authorized in Europe for Early Symptomatic Alzheimer Disease
September 29, 2025

The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.

Alcohol Use at Any Level Linked to Higher Dementia Risk, Large Study Finds
September 24, 2025

A study of more than 559 000 adults and 2.4 million genetic samples found that alcohol consumption of any amount increases dementia risk, challenging prior evidence of protective effects from light drinking.

Emerging Tau-Targeting Antibody for Alzheimer Disease Receives FDA Fast Track Designation
September 23, 2025

FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.

Alzheimer Disease: New Brain Targets and the New Drug Pipeline
September 17, 2025

Among 180+ active AD trials, 15 biological targets span traditional Aβ and tau proteins as well as new pathways in brain metabolism, neuroinflammation, and synaptic health.

Subcutaneous Leqembi Autoinjector Gains FDA Approval for Maintenance Use in Early Alzheimer Disease: Daily Dose
September 12, 2025

Your daily dose of the clinical news you may have missed.

Oral Blarcamesine Shows Marked Reduction in Cognitive Decline in Early Alzheimer Disease: Phase 2b/3 Data
September 11, 2025

Once-daily blarcamesine was associated with minimal cognitive decline at 48 weeks, with changes comparable to those observed in prodromal aging.

FDA Approves Subcutaneous Leqembi Autoinjector for Maintenance Therapy in Early Alzheimer Disease
September 01, 2025

The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.

PET Imaging Validates Direct Brain Delivery of Intranasal Insulin in Alzheimer Disease: Daily Dose
August 27, 2025

Your daily dose of the clinical news you may have missed.

Mediterranean Diet Linked to Reduced Risk of Dementia, Especially in Groups With High Genetic Risk
August 25, 2025

The protective effect of the diet was strongest in the highest-risk group, those homozygous for the APOE4 gene variant, suggesting that diet may help offset genetic risk.